<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37265174</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1296</StartPage><EndPage>1304</EndPage><MedlinePgn>1296-1304</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51821</ELocationID><Abstract><AbstractText Label="OBJECTIVE">No efficacious treatments exist to improve or prolong bulbar functions of speech and swallowing in persons with amyotrophic lateral sclerosis (pALS). This study evaluated the short-term impact of dextromethorphan/quinidine (DMQ) treatment on speech and swallowing function in pALS.</AbstractText><AbstractText Label="METHODS">This was a cohort trial conducted between August 2019 to August 2021 in pALS with a confirmed diagnosis of probable-definite ALS (El-Escorial Criteria-revisited) and bulbar impairment (ALS Functional Rating Scale score&#x2009;&#x2264;&#x2009;10 and speaking rate&#x2009;&#x2264;&#x2009;140 words per minute) who were DMQ na&#xef;ve. Efficacy of DMQ was assessed via pre-post change in the ALS Functional Rating Scale-Revised bulbar subscale and validated speech and swallowing outcomes. Paired t-tests, Fisher's exact, and &#x3c7;<sup>2</sup> tests were conducted with alpha at 0.05.</AbstractText><AbstractText Label="RESULTS">Twenty-eight pALS enrolled, and 24 participants completed the 28-day trial of DMQ. A significant increase in ALSFRS-R bulbar subscale score pre- (7.47&#x2009;&#xb1;&#x2009;1.98) to post- (8.39&#x2009;&#xb1;&#x2009;1.79) treatment was observed (mean difference: 0.92, 95% CI: 0.46-1.36, p&#x2009;&lt;&#x2009;0.001). Functional swallowing outcomes improved, with a reduction in unsafe (75% vs. 44%, p&#x2009;=&#x2009;0.003) and inefficient swallowing (67% vs. 58%, p&#x2009;=&#x2009;0.002); the relative speech event duration in a standard reading passage increased, indicating a greater duration of uninterrupted speech (mean difference: 0.33&#x2009;s, 95% CI: 0.02-0.65, p&#x2009;=&#x2009;0.035). No differences in diadochokinetic rate or speech intelligibility were observed (p&#x2009;&gt;&#x2009;0.05).</AbstractText><AbstractText Label="INTERPRETATION">Results of this study provide preliminary evidence that DMQ pharmacologic intervention may have the potential to improve or maintain bulbar function in pALS.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tabor Gray</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0792-2003</Identifier><AffiliationInfo><Affiliation>Aerodigestive Research Core, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Collaborative Research, Nova Southeastern University, Fort Lauderdale, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locatelli</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Collaborative Research, Nova Southeastern University, Fort Lauderdale, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasilopoulos</LastName><ForeName>Terrie</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wymer</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Aerodigestive Research Core, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plowman</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Aerodigestive Research Core, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Speech, Language and Hearing Sciences, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7355X3ROTS</RegistryNumber><NameOfSubstance UI="D003915">Dextromethorphan</NameOfSubstance></Chemical><Chemical><RegistryNumber>ITX08688JL</RegistryNumber><NameOfSubstance UI="D011802">Quinidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003915" MajorTopicYN="N">Dextromethorphan</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011802" MajorTopicYN="N">Quinidine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003679" MajorTopicYN="N">Deglutition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013060" MajorTopicYN="N">Speech</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>13</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37265174</ArticleId><ArticleId IdType="pmc">PMC10424659</ArticleId><ArticleId IdType="doi">10.1002/acn3.51821</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Onesti E, Schettino I, Gori MC, et&#xa0;al. Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet adaptation, and riluzole management. Front Neurol. 2017;8:94. doi:10.3389/fneur.2017.00094</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00094</ArticleId><ArticleId IdType="pmc">PMC5359548</ArticleId><ArticleId IdType="pubmed">28377742</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter RJ 3rd, McDonald TJ, Howard FM Jr. The otolaryngologic presentation of amyotrophic lateral sclerosis. Otolaryngology. 1978;86(3):ORL479&#x2010;ORL484.</Citation><ArticleIdList><ArticleId IdType="pubmed">112540</ArticleId></ArticleIdList></Reference><Reference><Citation>Hecht M, Hillemacher T, Grasel E, et&#xa0;al. Subjective experience and coping in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(4):225&#x2010;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">12710513</ArticleId></ArticleIdList></Reference><Reference><Citation>Boitano LJ. Management of airway clearance in neuromuscular disease. Respir Care. 2006;51(8):913&#x2010;922. discussion 922&#x2010;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">16867201</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C, Desport JC, Clavelou P, et&#xa0;al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009;256(8):1236&#x2010;1242. doi:10.1007/s00415-009-5100-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5100-z</ArticleId><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabor L, Gaziano J, Watts S, Robison R, Plowman EK. Defining swallowing&#x2010;related quality of life in individuals with amyotrophic lateral sclerosis. Dysphagia. 2016;31:376&#x2010;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4871719</ArticleId><ArticleId IdType="pubmed">26837611</ArticleId></ArticleIdList></Reference><Reference><Citation>Albuquerque KM, Pernambuco L, Lopes LW. Impact of drug treatment on voice, speech, and swallowing in patients with amyotrophic lateral sclerosis: a systematic review. Audiol Commun Res. 2022;27:e2599. doi:10.1590/2317-6431-2021-2599</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/2317-6431-2021-2599</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et&#xa0;al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence&#x2010;based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227&#x2010;1233. doi:10.1212/WNL.0b013e3181bc01a4</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc01a4</ArticleId><ArticleId IdType="pmc">PMC2764728</ArticleId><ArticleId IdType="pubmed">19822873</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hnlein P, Gdynia H&#x2010;J, Sperfeld A&#x2010;D, et&#xa0;al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol. 2008;4(7):366&#x2010;375. doi:10.1038/ncpneuro0853</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpneuro0853</ArticleId><ArticleId IdType="pubmed">18560390</ArticleId></ArticleIdList></Reference><Reference><Citation>Plowman EK, Tabor LC, Wymer J, Pattee G. The evaluation of bulbar dysfunction in amyotrophic lateral sclerosis: survey of clinical practice patterns in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:351&#x2010;357. doi:10.1080/21678421.2017.1313868</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1313868</ArticleId><ArticleId IdType="pmc">PMC7001984</ArticleId><ArticleId IdType="pubmed">28425762</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogus&#x2010;Pulia NM, Plowman EK. Shifting tides toward a proactive patient&#x2010;centered approach in dysphagia management of neurodegenerative disease. Am J Speech Lang Pathol. 2020;29(2s):1094&#x2010;1109. doi:10.1044/2020_ajslp-19-00136</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/2020_ajslp-19-00136</ArticleId><ArticleId IdType="pmc">PMC7844336</ArticleId><ArticleId IdType="pubmed">32650651</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattee GL, Plowman EK, Focht Garand KL, et&#xa0;al. Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis. Muscle Nerve. 2019;59(5):531&#x2010;536. doi:10.1002/mus.26408</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26408</ArticleId><ArticleId IdType="pubmed">30620104</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Pioro E, Myers K, et&#xa0;al. Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial. Neurotherapeutics. 2017;14(3):762&#x2010;772. doi:10.1007/s13311-016-0508-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0508-5</ArticleId><ArticleId IdType="pmc">PMC5509619</ArticleId><ArticleId IdType="pubmed">28070747</ArticleId></ArticleIdList></Reference><Reference><Citation>Green JR, Allison KM, Cordella C, et&#xa0;al. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: a quantitative speech analysis. Br J Clin Pharmacol. 2018;84(12):2849&#x2010;2856. doi:10.1111/bcp.13745</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13745</ArticleId><ArticleId IdType="pmc">PMC6256051</ArticleId><ArticleId IdType="pubmed">30152872</ArticleId></ArticleIdList></Reference><Reference><Citation>Pioro EP. Review of dextromethorphan 20 mg/quinidine 10 mg (NUEDEXTA(&#xae;)) for pseudobulbar affect. Neurol Ther. 2014;3(1):15&#x2010;28. doi:10.1007/s40120-014-0018-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40120-014-0018-5</ArticleId><ArticleId IdType="pmc">PMC4381919</ArticleId><ArticleId IdType="pubmed">26000221</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et&#xa0;al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13&#x2010;21. doi:10.1016/S0022-510X(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele CM, Namasivayam&#x2010;MacDonald AM, Guida BT, et&#xa0;al. Creation and initial validation of the international dysphagia diet standardisation initiative functional diet scale. Arch Phys Med Rehabil. 2018;99(5):934&#x2010;944. doi:10.1016/j.apmr.2018.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apmr.2018.01.012</ArticleId><ArticleId IdType="pmc">PMC5961739</ArticleId><ArticleId IdType="pubmed">29428348</ArticleId></ArticleIdList></Reference><Reference><Citation>Waito AA, Plowman EK, Barbon CEA, et&#xa0;al. A cross&#x2010;sectional, quantitative videofluoroscopic analysis of swallowing physiology and function in individuals with amyotrophic lateral sclerosis. J Speech Lang Hear Res. 2020;63(4):948&#x2010;962. doi:10.1044/2020_jslhr-19-00051</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/2020_jslhr-19-00051</ArticleId><ArticleId IdType="pmc">PMC7242989</ArticleId><ArticleId IdType="pubmed">32310713</ArticleId></ArticleIdList></Reference><Reference><Citation>Plowman EK, Tabor&#x2010;Gray L, Rosado KM, et&#xa0;al. Impact of expiratory strength training in amyotrophic lateral sclerosis: results of a randomized, sham&#x2010;controlled trial. Muscle Nerve. 2019;59(1):40&#x2010;46. doi:10.1002/mus.26292</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26292</ArticleId><ArticleId IdType="pubmed">29981250</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabor L, Gaziano J, Watts S, Robison R, Plowman EK. Defining swallowing&#x2010;related quality of life profiles in individuals with amyotrophic lateral sclerosis. Dysphagia. 2016;31(3):376&#x2010;382. doi:10.1007/s00455-015-9686-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00455-015-9686-2</ArticleId><ArticleId IdType="pmc">PMC4871719</ArticleId><ArticleId IdType="pubmed">26837611</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutcheson KA, Barrow MP, Barringer DA, et&#xa0;al. Dynamic Imaging Grade of Swallowing Toxicity (DIGEST): scale development and validation. Cancer. 2017;123(1):62&#x2010;70. doi:10.1002/cncr.30283</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.30283</ArticleId><ArticleId IdType="pmc">PMC5161634</ArticleId><ArticleId IdType="pubmed">27564246</ArticleId></ArticleIdList></Reference><Reference><Citation>Plowman EY, DiBiase L, Segalewitz T, et&#xa0;al. Psychometric validation of the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) for use in individuals with amyotrophic lateral sclerosis. 29th Annual Dysphagia Research Society, 23 September 2021, Virtual, Session Oral Presentation 2021.</Citation></Reference><Reference><Citation>Hutcheson KA, Barbon CEA, Alvarez CP, Warneke CL. Refining measurement of swallowing safety in the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) criteria: validation of DIGEST version 2. Cancer. 2022;128(7):1458&#x2010;1466. doi:10.1002/cncr.34079</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.34079</ArticleId><ArticleId IdType="pmc">PMC8917062</ArticleId><ArticleId IdType="pubmed">34985765</ArticleId></ArticleIdList></Reference><Reference><Citation>Yunusova Y, Green JR, Wang J, Pattee G, Zinman L. A protocol for comprehensive assessment of bulbar dysfunction in amyotrophic lateral sclerosis (ALS). J Vis Exp. 2011;48:e2422. doi:10.3791/2422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2422</ArticleId><ArticleId IdType="pmc">PMC3197394</ArticleId><ArticleId IdType="pubmed">21372794</ArticleId></ArticleIdList></Reference><Reference><Citation>Yorkston K, Beukelman D, Hakel M, Dorsey M. Speech Intelligibility Test for Windows. Institute for Rehabilitation Science and Engineering at Madonna Rehabilitation Hospital; 2007:103.</Citation></Reference><Reference><Citation>Smith RA, Wicks P, Yagi N, Scheinker D, Thisted R. Development of a self report bulbar function scale (CNS&#x2010;BFS). Neurology. 2011;76(9):A48&#x2010;A49.</Citation></Reference><Reference><Citation>Belafsky PC, Mouadeb DA, Rees CJ, et&#xa0;al. Validity and reliability of the Eating Assessment Tool (EAT&#x2010;10). Ann Otol Rhinol Laryngol. 2008;117(12):919&#x2010;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">19140539</ArticleId></ArticleIdList></Reference><Reference><Citation>Oki R, Izumi Y, Fujita K, et&#xa0;al. Efficacy and safety of ultrahigh&#x2010;dose methylcobalamin in early&#x2010;stage amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2022;79(6):575&#x2010;583. doi:10.1001/jamaneurol.2022.0901</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.0901</ArticleId><ArticleId IdType="pmc">PMC9086935</ArticleId><ArticleId IdType="pubmed">35532908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Bedlack R, Andrews JA, et&#xa0;al. Amyotrophic lateral sclerosis clinical trials and interpretation of functional end points and fluid biomarkers: a review. JAMA Neurol. 2022;79:1312&#x2010;1318. doi:10.1001/jamaneurol.2022.3282</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.3282</ArticleId><ArticleId IdType="pubmed">36251310</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et&#xa0;al. Trial of sodium phenylbutyrate&#x2013;taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919&#x2010;930. doi:10.1056/NEJMoa1916945</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong P, Yunusova Y, Wang J, et&#xa0;al. Predicting speech intelligibility decline in amyotrophic lateral sclerosis based on the deterioration of individual speech subsystems. PLoS ONE. 2016;11(5):e0154971. doi:10.1371/journal.pone.0154971</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0154971</ArticleId><ArticleId IdType="pmc">PMC4858181</ArticleId><ArticleId IdType="pubmed">27148967</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong P, Yunusova Y, Wang J, Green JR. Predicting early bulbar decline in amyotrophic lateral sclerosis: a speech subsystem approach. Behav Neurol. 2015;2015:183027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468279</ArticleId><ArticleId IdType="pubmed">26136624</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta&#xae;) clinical use. Pharmacol Ther. 2016;164:170&#x2010;182. doi:10.1016/j.pharmthera.2016.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2016.04.010</ArticleId><ArticleId IdType="pubmed">27139517</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieger D. Role of bulbar serotonergic neurotransmission in the initiation of swallowing in the rat. Neuropharmacology. 1981;20(11):1073&#x2010;1083. doi:10.1016/0028-3908(81)90099-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0028-3908(81)90099-X</ArticleId><ArticleId IdType="pubmed">7322284</ArticleId></ArticleIdList></Reference><Reference><Citation>Jean A. Brain stem control of swallowing: neuronal network and cellular mechanisms. Physiol Rev. 2001;81(2):929&#x2010;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler JP, Jean A. Inhibition of the swallowing reflex by local application of serotonergic agents into the nucleus of the solitary tract. Eur J Pharmacol. 1985;118(1&#x2013;2):77&#x2010;85. doi:10.1016/0014-2999(85)90665-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(85)90665-x</ArticleId><ArticleId IdType="pubmed">4085551</ArticleId></ArticleIdList></Reference><Reference><Citation>Haney MM, Sinnott J, Osman KL, et&#xa0;al. Mice lacking brain&#x2010;derived serotonin have altered swallowing function. Otolaryngol Head Neck Surg. 2019;161(3):468&#x2010;471. doi:10.1177/0194599819846109</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599819846109</ArticleId><ArticleId IdType="pmc">PMC8341204</ArticleId><ArticleId IdType="pubmed">31035861</ArticleId></ArticleIdList></Reference><Reference><Citation>El Oussini H, Bayer H, Scekic&#x2010;Zahirovic J, et&#xa0;al. Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis. Acta Neuropathol. 2016;131(3):465&#x2010;480. doi:10.1007/s00401-016-1534-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1534-4</ArticleId><ArticleId IdType="pubmed">26744351</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnoux A, Ayme&#x2010;Dietrich E, Dieterle S, et&#xa0;al. Evaluation of a 5&#x2010;HT2B receptor agonist in a murine model of amyotrophic lateral sclerosis. Sci Rep. 2021;11(1):23582. doi:10.1038/s41598-021-02900-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02900-0</ArticleId><ArticleId IdType="pmc">PMC8654833</ArticleId><ArticleId IdType="pubmed">34880312</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>